These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36523794)

  • 21. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
    Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F
    J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Morano F; Corallo S; Niger M; Barault L; Milione M; Berenato R; Moretto R; Randon G; Antista M; Belfiore A; Raimondi A; Nichetti F; Martinetti A; Battaglia L; Perrone F; Pruneri G; Falcone A; Di Bartolomeo M; de Braud F; Di Nicolantonio F; Cremolini C; Pietrantonio F
    Ann Oncol; 2018 Aug; 29(8):1800-1806. PubMed ID: 29860358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
    Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
    Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
    Hassel JC; Sucker A; Edler L; Kurzen H; Moll I; Stresemann C; Spieth K; Mauch C; Rass K; Dummer R; Schadendorf D
    Br J Cancer; 2010 Sep; 103(6):820-6. PubMed ID: 20736948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
    Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M
    PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
    Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
    Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Clinical Significance of O
    Zhao YH; Wang ZF; Cao CJ; Weng H; Xu CS; Li K; Li JL; Lan J; Zeng XT; Li ZQ
    Front Neurol; 2018; 9():127. PubMed ID: 29619003
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
    Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
    Lattanzio L; Borgognone M; Mocellini C; Giordano F; Favata E; Fasano G; Vivenza D; Monteverde M; Tonissi F; Ghiglia A; Fillini C; Bernucci C; Merlano M; Lo Nigro C
    Int J Biol Markers; 2015 May; 30(2):e208-16. PubMed ID: 25588856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGMT promoter methylation in Peruvian patients with glioblastoma.
    Belmar-Lopez C; Castaneda CA; Castillo M; García-Corrochano P; Orrego E; Meléndez B; Casavilca S; Flores C; Orrego E
    Ecancermedicalscience; 2018; 12():812. PubMed ID: 29515653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
    Jakob J; Hille M; Sauer C; Ströbel P; Wenz F; Hohenberger P
    Radiat Oncol; 2012 Oct; 7():180. PubMed ID: 23110891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.